Company intelligence / Profile preview

CardiolRx

Oakville, Ontario, Canada

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Cardiol Therapeutics is a clinical-stage life sciences company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation being investigated in Phase 2 clinical trials for recurrent pericarditis and acute myocarditis. Additionally, Cardiol is developing CRD-38, a subcutaneous formulation of cannabidiol intended for the treatment of heart failure. By targeting inflammatory pathways, the company aims to provide new treatment options for patients with inflammatory heart conditions who have limited therapeutic alternatives.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CardiolRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardiolRx.

Explore the full profile